Fig. 1 Validation of hNRASD12 expression in the β-actin:LDL-hNRASD12;lmo2:Cre transgenic embryos. (A) Diagrammatic scheme of the β-actin-LDL-hNRASD12 transgenic construct. (B-D) The expression analyses of the hNRASD12 transcripts via whole mount in situ hybridization (WISH) in the β-actin:LDL-hNRASD12;lmo2:Cre embryo (hereafter referred as hNRASD12 embryo) (B) and β-actin:LDL-hNRASD12;wild-type embryo (hereafter referred as control embryo) (C) respectively at 22 hours post fertilization (hpf), and lom2 transcripts in the wild-type embryo at 22 hpf (D). Black arrows denote the location of the intermediate cell mass (ICM) region. (E) Confirmation of the expression of hNRAS protein in the hNRASD12-embryos at 28 hpf via western blotting analysis.
Image
Figure Caption
Figure Data
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Full text @ J. Hematol. Oncol.